814MO Phase II study of olaparib (O) plus durvalumab (D) and bevacizumab (B) (MEDIOLA): Initial results in patients (pts) with non-germline BRCA-mutated (non-gBRCAm) platinum sensitive relapsed (PSR) ovarian cancer (OC)

Yvette Drew, Richard T. Penson, David M. O’Malley, JW Kim, Stefan Zimmermann, Patricia Roxburgh, Joohyuk Sohn, Salomon M. Stemmer, Sara Bastian, Michelle Ferguson,

Annals of Oncology · 2020 · 61 citations · 0 references

DOIFull text

Open access

Concepts